Comparative adherence to oxybutynin or tolterodine among older patients
- PMID: 21710237
- DOI: 10.1007/s00228-011-1090-8
Comparative adherence to oxybutynin or tolterodine among older patients
Abstract
Purpose: To compare persistence of oxybutynin or tolterodine therapy among older patients newly prescribed one of these drugs.
Methods: We conducted a retrospective cohort study of Ontarians aged 66 years and older who were newly prescribed either drug between January 1, 2000 and December 31, 2007. Persistence with treatment was defined on the basis of refills for the drug within a grace period equal to 50% of the prescription duration.
Results: We identified 31,996 patients newly treated with oxybutynin and 24,855 newly treated with tolterodine. After 2 years of follow-up, persistence on oxybutynin (9.4%) was significantly lower than that on tolterodine (13.6%, p < 0.0001). The median time to discontinuation of oxybutynin and tolterodine was 68 and 128 days, respectively.
Conclusions: Our findings suggest that the tolerability of these drugs differs substantially.
Comment in
-
Comparative adherence to oxybutynin or tolterodine among older patients.Eur J Clin Pharmacol. 2012 Jul;68(7):1119; author reply 1121. doi: 10.1007/s00228-012-1224-7. Epub 2012 Feb 15. Eur J Clin Pharmacol. 2012. PMID: 22349160 No abstract available.
Similar articles
-
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.J Manag Care Pharm. 2008 Apr;14(3):291-301. doi: 10.18553/jmcp.2008.14.3.291. J Manag Care Pharm. 2008. PMID: 18439051 Free PMC article.
-
Comparative adherence to oxybutynin or tolterodine among older patients.Eur J Clin Pharmacol. 2012 Jul;68(7):1119; author reply 1121. doi: 10.1007/s00228-012-1224-7. Epub 2012 Feb 15. Eur J Clin Pharmacol. 2012. PMID: 22349160 No abstract available.
-
Risk of serious falls associated with oxybutynin and tolterodine: a population based study.J Urol. 2011 Oct;186(4):1340-4. doi: 10.1016/j.juro.2011.05.077. J Urol. 2011. PMID: 21855905
-
Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Indian J Physiol Pharmacol. 2013. PMID: 24968572 Review.
-
The newer antimuscarinic drugs: bladder control with less dry mouth.Cleve Clin J Med. 2002 Oct;69(10):761, 765-6, 768-9. doi: 10.3949/ccjm.69.10.761. Cleve Clin J Med. 2002. PMID: 12371799 Review.
Cited by
-
Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.Neurourol Urodyn. 2022 Nov;41(8):1872-1889. doi: 10.1002/nau.25040. Epub 2022 Sep 13. Neurourol Urodyn. 2022. PMID: 36098417 Free PMC article.
-
Efficacy of posterior tibial nerve stimulation (PTNS) on overactive bladder in older adults.Eur Geriatr Med. 2018 Apr;9(2):249-253. doi: 10.1007/s41999-017-0013-3. Epub 2018 Jan 5. Eur Geriatr Med. 2018. PMID: 34654250
-
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
-
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.BMJ Open. 2018 Nov 21;8(11):e021889. doi: 10.1136/bmjopen-2018-021889. BMJ Open. 2018. PMID: 30467131 Free PMC article.
-
Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization.J Am Heart Assoc. 2018 Aug 21;7(16):e009745. doi: 10.1161/JAHA.118.009745. J Am Heart Assoc. 2018. PMID: 30369318 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
